



ASX Announcement

CHANGE OF AUDITOR AND AUDIT STANDARDS

Atlanta, Georgia USA - 30 November 2017: Pursuant to the requirements of Listing Rule 3.16.3, Visioneering Technologies, Inc (ASX: VTI) (**Company**) advises that Grant Thornton LLP will take over the role of auditor of the Company with effect from 30 November 2017.

The respective details of the outgoing and incoming auditors are provided below:

Outgoing auditor: Grant Thornton Audit Pty Ltd
Level 17, 383 Kent Street
Sydney NSW 2000
Australia

Incoming auditor: Grant Thornton LLP
1100 Peachtree St. NE
Suite 1200
Atlanta GA 30309
United States of America

The Company has determined that management of the audit should be located in Grant Thornton's Atlanta office rather than the Sydney office. In addition, the Company has determined that auditing standards generally accepted in the United States of America (US Auditing Standards) will apply to the Company's audited accounts going-forward rather than International Auditing Standards.

Leanne Ralph
Company Secretary

About VTI:

Visioneering Technologies, Inc. (VTI) is a US-based medical device company primarily engaged in the design, manufacture, sale and distribution of a revolutionary new contact lens: the NaturalVue™ Multifocal (MF) contact lens. The NaturalVue MF contact lens employs VTI's Neurofocus Optics™ technology, which was developed, refined and tested over many years. The characteristics of the NaturalVue MF contact lens allow it to be used in two of the largest eye-care markets globally: adults with presbyopia (age-related difficulty in seeing close objects) and children with myopia (near-sightedness, or difficulty seeing distant objects).

NaturalVue lenses were cleared by the FDA in late 2014 and VTI recently commenced its US market expansion for NaturalVue MF contact lenses, following a successful pilot US market launch in 2015 and 2016. VTI also sells and plans additional contact lens products.

Foreign ownership restrictions:

VTI's CHESD Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US.

Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.